Stockscreener 앱 받기
13.26
3.51%
0.45
시장 영업 전:
13.20
-0.06
-0.45%
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review
Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Intellia rises on Q4 earnings & revenue beat, focuses on pipeline - MSN
Intellia jumps as FDA lifts clinical hold on Nex-Z for ATTR-CM - MSN
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - MSN
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat
Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Acti - GuruFocus
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing? - Sahm
Intellia Therapeutics at Leerink Global Healthcare Conference: Gene Editing Prospects - Investing.com Canada
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha
NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Intellia Therapeutics Q4 2025 earnings preview - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA) - The Globe and Mail
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
FDA’s lifting of clinical holds sends Intellia upwards - The Pharma Letter
Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran - National Today
Intellia Therapeutics (NTLA) Highlights Promising Findings in He - GuruFocus
NTLA: Leerink Partners Raises Price Target and Maintains Outperf - GuruFocus
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
NTLA: RBC Capital Raises Price Target to $15, Maintains Sector P - GuruFocus
Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Sahm
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - Bitget
Wells Fargo & Company Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
Citizens Jmp Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price - MarketBeat
HC Wainwright Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $30.00 - MarketBeat
Vanguard Group Inc. Acquires 192,651 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating - marketscreener.com
NTLA Sees Price Target Raised by Citizens, Rating Maintained | N - GuruFocus
Intellia presents data on experimental gene therapy for hereditary angioedema - Investing.com
RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk - marketscreener.com
NTLA: HC Wainwright & Co. Raises Price Target to $30.00 | NTLA S - GuruFocus
1.82%
자본화:
|
볼륨(24시간):